[HTML][HTML] Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
Background Targeted therapies in metastatic renal cell carcinoma (mRCC) have been
approved based on registration clinical trials that have strict eligibility criteria. The clinical …
approved based on registration clinical trials that have strict eligibility criteria. The clinical …
Progression‐free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy
DYC Heng, W Xie, GA Bjarnason, U Vaishampayan… - Cancer, 2011 - Wiley Online Library
BACKGROUND. The majority of metastatic renal cell carcinoma (mRCC) clinical trials that
examined targeted agents used progression‐free survival (PFS) as the primary endpoint …
examined targeted agents used progression‐free survival (PFS) as the primary endpoint …
Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices
E Jonasch, JE Signorovitch, PL Lin, Z Liu… - … medical research and …, 2014 - Taylor & Francis
Background: Vascular endothelial growth factor (VEGF) inhibitors, including targeted
therapy with tyrosine kinase inhibitors (TKIs) and the angiogenesis inhibitor bevacizumab …
therapy with tyrosine kinase inhibitors (TKIs) and the angiogenesis inhibitor bevacizumab …
[HTML][HTML] Survival of patients with advanced or metastatic renal cell carcinoma in routine practice differs from that in clinical trials—analyses from the German Clinical …
N Marschner, M Staehler, L Müller, A Nusch… - Clinical genitourinary …, 2017 - Elsevier
Introduction Because “real-life” patients often do not meet the strict eligibility criteria of
clinical trials, we assessed the trial eligibility of patients with advanced or metastatic renal …
clinical trials, we assessed the trial eligibility of patients with advanced or metastatic renal …
Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice
AP Mitchell, MR Harrison, MS Walker… - Journal of oncology …, 2015 - ascopubs.org
Purpose: Although narrow eligibility criteria improve the internal validity of clinical trials, they
may result in differences between study populations and real-world patients, threatening …
may result in differences between study populations and real-world patients, threatening …
Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world observational …
DY Heng, J Signorovitch, E Swallow, N Li, Y Zhong… - PloS one, 2014 - journals.plos.org
Objective The optimal sequencing of targeted therapies for metastatic renal cell carcinoma
(mRCC) is unknown. Observational studies with a variety of designs have reported differing …
(mRCC) is unknown. Observational studies with a variety of designs have reported differing …
[HTML][HTML] Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer …
AV Soerensen, F Donskov, GG Hermann… - European Journal of …, 2014 - Elsevier
Aim To evaluate the implementation of targeted therapy on overall survival (OS) in a
complete national cohort of patients with metastatic renal cell carcinoma (mRCC). Methods …
complete national cohort of patients with metastatic renal cell carcinoma (mRCC). Methods …
Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era
Background Recent phase III studies of targeted agents for metastatic renal cell carcinoma
(mRCC) have generated median survival estimates that far exceed those observed during …
(mRCC) have generated median survival estimates that far exceed those observed during …
Outcomes for patients with metastatic renal cell carcinoma achieving a complete response on targeted therapy: a registry-based analysis
T Buchler, Z Bortlicek, A Poprach, T Pavlik… - European urology, 2016 - Elsevier
Background It is currently not known whether treatment with anti–vascular endothelial
growth factor agents for metastatic renal cell carcinoma (mRCC) can be safely discontinued …
growth factor agents for metastatic renal cell carcinoma (mRCC) can be safely discontinued …
[HTML][HTML] Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma
SJ Hotte, GA Bjarnason, DYC Heng, MAS Jewett… - Current …, 2011 - ncbi.nlm.nih.gov
Traditionally, overall survival (os) has been considered the “gold standard” for evaluating
new systemic oncologic therapies, because death is easy to define, is easily compared …
new systemic oncologic therapies, because death is easy to define, is easily compared …